Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,111

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home

Open access
Koopman, Maria M.W., Prandoni, Paolo, Piovella, Franco, Ockelford, Paul A., Brandjes, Desiderius P.M., van der Meer, Jan, Gallus, Alexander S., Simonneau, Gérald, Chesterman, Colin H., Prins, Martin H., Bossuyt, Patrick M.M., de Haes, Hanneke, van den Belt, Angelique G.M., Sagnard, Luc, d'Azemar, Pascal, Büller, Harry R.·1996·New England Journal of Medicine

Abstract

BACKGROUND: An intravenous course of standard (unfractionated) heparin with the dose adjusted to prolong the activated partial-thromboplastin time to a desired length is the standard initial in-hospital treatment for patients with deep-vein thrombosis, but fixed-dose subcutaneous low-molecular-weight heparin appears to be as effective and safe. Because the latter treatment can be given on an outpatient basis, we compared the two treatments in symptomatic outpatients with proximal-vein thrombosis but no signs of pulmonary embolism. METHODS: We randomly assigned patients to adjusted-dose intravenous standard heparin administered in the hospital (198 patients) or fixed-dose subcutaneous low-molecular-weight heparin administered at home, when feasible (202 patients). We compared the treatments with respect to recurrent venous thromboembolism, major bleeding, quality of life, and costs. RESULTS: Seventeen of the 198 patients who received standard heparin (8.6 percent) and 14 of the 202 patients who received low-molecular-weight heparin (6.9 percent) had recurrent thromboembolism (difference, 1.7 percentage points; 95 percent confidence interval, -3.6 to 6.9). Major bleeding occurred in four patients assigned to standard heparin (2.0 percent) and one patient assigned to low-molecular-weight heparin (0.5 percent; difference, 1.5 percentage points; 95 percent confidence interval, -0.7 to 2.7). Quality of life improved in both groups. Physical activity and social functioning were better in the patients assigned to low-molecular-weight heparin. Among the patients in that group, 35 percent were never admitted to the hospital at all, and 40 percent were discharged early. This treatment was associated with a mean reduction in hospital days of 67 percent, ranging from 29 percent to 86 percent in the various study centers. CONCLUSIONS: In patients with proximal-vein thrombosis, treatment with low-molecular-weight heparin at home is feasible, effective, and safe.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199603143341102

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 1,111

Metadata

Authors
Koopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P. A., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C. H., Prins, M. H., Bossuyt, P. M. M., de Haes, H., van den Belt, A. G. M., Sagnard, L., d'Azemar, P., & Büller, H. R.
Venue
New England Journal of Medicine
Published
1996-03-14
Volume
334
Issue
11
Pages
682-687
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2342200163
Cited by
1,111
References
25
FWCI
52.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home. https://app.cochat.ai/papers/10.1056/nejm199603143341102
The paper
Koopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P. A., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C. H., Prins, M. H., Bossuyt, P. M. M., de Haes, H., van den Belt, A. G. M., Sagnard, L., d'Azemar, P., & Büller, H. R. (1996). Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home. New England Journal of Medicine. https://doi.org/10.1056/nejm199603143341102

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.